PhD Scientific Days 2022

Clinical Medicine IV.

Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals – Prospective observational cohort study

Előadó neve

Dr. Piros, Éva Anna

Előadó munkahelye

Semmelweis University, Department of Dermatology, Venereology and Dermatooncology

Előadó telefonszáma

+36306183568

Előadó e-mail címe

piros.anna95@gmail.com

Az előadás címe

Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals – Prospective observational cohort study

Szerző(k) neve és munkahelye

Éva Anna Piros 1,2, Orsolya Cseprekál 3,4, Anna Görög 1, Bernadett Hidvégi 1, Márta Medvecz 1, Zsófia Szabó 5, Ferenc Olajos 5, Eszter Barabás 5, Noémi Galajda 1, Pál Miheller 6,*, Péter Holló 1,*

1 Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary
2 Rácz Károly Doctoral School of Clinical Medicine, Semmelweis University, Budapest, Hungary
3 Department of Surgery, Transplantation and Gastroenterology, Semmelweis University, Budapest, Hungary
4 International Nephrology Research and Training Center (INRTC), Budapest, Hungary
5 Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary
6 1st Department of Surgery and Interventional Gastroenterology, Semmelweis University, Budapest, Hungary
*These two authors have shared last authorship/contributed equally to the publication

Bemutatás módja

Szóbeli

Szekció

Clinical Medicine IV.

Language of the presentation

Hungarian

Preferred session

Clinical Medicine

Összefoglaló szövege

Introduction: It is unclear whether biological antipsoriatic therapies affect seroconversion after messenger ribonucleic acid (mRNA)-based anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) vaccinations.

Aims: To assess antibody formation and the incidence of side effects after anti-SARS-CoV-2 mRNA vaccinations in psoriatic patients receiving different biologicals compared to healthy controls.

Method: 102 moderate-to-severe psoriatic patients (56,2 (±13,5) years) and 55 age-matched healthy (56,4±13,6 years) volunteers were included in our study. Ten to 21 days after the administration of the second dosage of BNT162b2 or mRNA-1273 vaccine, antibody levels specific to the SARS-CoV-2 spike (S) protein receptor binding domain were monitored. The incidence of postvaccination side effects was recorded and compared to real-life data in the literature.

Results: Of the 102 patients, 57 (55,88%) received tumor necrosis factor (TNF), 28 (27,45%) received interleukin (IL)-12/23, 16 (15,68%) received IL-17, and 1 (0,99%) received IL-23 inhibitors. No significant differences in the median serum level of anti-SARS-CoV-2S antibody were observed between the study population and the control group (median IQR range: 1681,0 U/ml (600,0-4844,0) vs. 1984,0 U/ml (1000,0-3136,0; p=0,82). The most frequent side effects of the mRNA vaccines within 7 days after the administration of both dosages were arm pain on the side of injection (23,53% and 23,53%), fatigue (9,80% and 13,72%), headache (4,9% and 5,88%) and chills or shivering (4,9% and 8,82%).

Conclusion: Detectable antibodies against SARS-CoV-2S protein appear 10-21 days after the administration of the second dosage of BNT162b2 or mRNA-1273 vaccines in moderate-to-severe psoriatic patients receiving biologicals, similar to those of healthy controls.

Funding sources: The study was founded by the grant: Investing in the Future Fund: „National level adjustments to the challenges of the SARS-CoV2 pandemic on blood banking operations”, ID No: 2020-1.1.6-JÖVŐ-2021-00010.

University and Doctoral School

Semmelweis University, Károly Rácz Doctoral School of Clinical Medicine

Supervisor

Prof. Dr. Péter Holló

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

5885

Start

14:30

End

14:45

Authors (legacy)

Éva Anna Piros 1,2, Orsolya Cseprekál 3,4, Anna Görög 1, Bernadett Hidvégi 1, Márta Medvecz 1, Zsófia Szabó 5, Ferenc Olajos 5, Eszter Barabás 5, Noémi Galajda 1, Pál Miheller 6,*, Péter Holló 1,*

1 Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary
2 Rácz Károly Doctoral School of Clinical Medicine, Semmelweis University, Budapest, Hungary
3 Department of Surgery, Transplantation and Gastroenterology, Semmelweis University, Budapest, Hungary
4 International Nephrology Research and Training Center (INRTC), Budapest, Hungary
5 Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary
6 1st Department of Surgery and Interventional Gastroenterology, Semmelweis University, Budapest, Hungary
*These two authors have shared last authorship/contributed equally to the publication